Publication

Article

Supplements and Featured Publications

Diagnosis and Trial Options in Sarcoma
Volume1
Issue 1

Exploring the Interaction of MDM2 and p53 in Soft Tissue Sarcomas

Articles in this issue
Javier Martin-Broto, MD, PhD,
Dr. Martin-Broto on Future Research Directions of Soft Tissue Sarcoma
Exploring the Interaction of MDM2 and p53 in Soft Tissue Sarcomas
Exploring the Interaction of MDM2 and p53 in Soft Tissue Sarcomas
Jean-Yves Blay, MD
Dr. Blay on Treatment Considerations in Soft Tissue Sarcomas
Patricia LoRusso, DO
Dr. LoRusso on the Benefit of Genetic Sequencing in Sarcomas
Javier Martin-Broto, MD, PhD
Dr. Martin-Broto on the Current First-Line Treatment of Soft Tissue Sarcomas
Javier Martin-Broto, MD, PhD
Dr. Martin-Broto on MDM2 and P53 in Soft Tissue Sarcoma
Javier Martin-Broto, MD, PhD
Dr. Martin-Broto on the Ongoing Research of MDM2 Agonists in Soft Tissue Sarcoma
Patricia LoRusso, DO
MDM2 Pulls Novel Treatments Into Focus for Underserved Liposarcoma Population
Patricia LoRusso, DO
Dr. LoRusso on the Importance of Clinical Trials in MDM2-Amplified Dedifferentiated Liposarcoma
Jean-Yves Blay, MD
Dr. Blay on the Current Treatment Challenges in Soft Tissue Sarcomas
Patricia LoRusso, DO
Dr. LoRusso on the Efficacy of BI 907828 in Solid Tumors
Jean-Yves Blay, MD
Dr. Blay on the Exploration of BI 907828 in Patients With Sarcoma
Related Videos
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
3 experts are featured in this series.
Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
2 experts in this video
2 experts in this video
Sagar D. Sardesai, MBBS
Related Content
Ovarian Cancer
December 20th 2024

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing
December 20th 2024

Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing

FDA
December 20th 2024

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer

Mazyar Shadman, MD, MPH, associate professor, Clinical Research Division, medical director, Cellular Immunotherapy, Fred Hutchinson Cancer Center
December 19th 2024

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

Lung Cancer | stock.adobe.com
December 20th 2024

China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC

Acute Myeloid Leukemia | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 20th 2024

Uproleselan Plus Chemo Fails to Improve OS in R/R AML in China